Some states are restricting the usage of this AstraZeneca vaccine even though some have resumed inoculations, as investigations into reports of infrequent, and at times acute, blood clots persist. The health officials said that they, nevertheless, still considered the benefits of the vaccine in preventing COVID-19 far outweigh any potential risk of blood clots.
The Medicines and Healthcare products Regulatory Agency on Thursday said it had received no reports of clotting events after use of this vaccine created by BioNTech SE and Pfizer Inc. On March 18, the UK medicines regulator stated there were five cases of a rare brain blood clot one of 11 million administered shots. On Thursday, it set the count at 22 reports of cerebral venous sinus thrombosis, a very rare brain clotting disease, and 8 accounts of additional clotting events connected with reduced blood platelets from a total of 18.1 million doses awarded.
British authorities said that they had identified 30 cases of infrequent blood clot events following the usage of this AstraZeneca COVID-19 vaccine, 25 more than the agency previously mentioned.